Cefuroxime is a second-generation cephalosporin antibiotic that has been widely available in the USA since 1977. It is also available under the brand name Ceftin. Glaxo Smith Kline sells the antibiotic in Australia (and other countries, such as Israel) under the name Zinnat (R), with the Australian pharmaceutical code of R 47621. In Poland it is produced by the Polish firm Bioton S.A. under the name Biofuroksym®.
According to the package insert supplied with Zinnat, Cefuroxime is manufactured as tablets as well as a sodium salt, the latter designed for medical injection.
As for the cephalosporins, although as a second-generation it is less susceptible to Beta-lactamase and so may have greater activity against Haemophilus influenzae, Neisseria gonorrhoeae and Lyme disease.
Cefuroxime is generally well tolerated and side effects are usually transient. Cefuroxime if taken with food is both better absorbed and less likely to cause its commonest upsets of diarrhea, nausea, vomiting and abdominal pain.
Although there is a widely quoted cross-allergy risk of 10% between cephalosporins and penicillin, an article in the Journal of Family Practice (February 2006) has shown no increased risk for cross-allergy for cefuroxime and several other 2nd generation or later cephalosporins.